Kuros Biosurgery closed the transaction merging Kuros with Cytos Biotechnology, originally announced at the end of 4Q15.
The combined entity, Kuros Biosciences, will continue development of orthobiologic products such as KUR-111 and KUR-113, designed to generate bone tissue to heal fractures and stabilize the spine.
Kuros Biosurgery closed the transaction merging Kuros with Cytos Biotechnology, originally announced at the end of 4Q15.
The combined entity, Kuros Biosciences, will continue development of orthobiologic products such as KUR-111 and KUR-113, designed to generate bone tissue to heal...
Kuros Biosurgery closed the transaction merging Kuros with Cytos Biotechnology, originally announced at the end of 4Q15.
The combined entity, Kuros Biosciences, will continue development of orthobiologic products such as KUR-111 and KUR-113, designed to generate bone tissue to heal fractures and stabilize the spine.
Copy to clipboard 
